Innovate Partnering with University of Maryland to Investigate Larazotide’s Potential to Treat IBD

Innovate Partnering with University of Maryland to Investigate Larazotide’s Potential to Treat IBD
Innovate Biopharmaceuticals Inc. will collaborate with a researcher at the University of Maryland School of Medicine to develop larazotide as a potential treatment for diseases that affect the intestinal barrier, the company announced. The intestine is composed of a layer of cells normally held tightly together to stop any foreign organisms from breaking the intestinal barrier. However, the permeability of the intestinal barrier can sometimes be compromised, leading to the development of intestinal diseases. This has led researchers to look for treatments that target intestinal permeability. Innovate’s lead therapy candidate, larazotide acetate, also known as INN-2o2, is a regulator of these cell-cell boundaries, called junctions, and helps restore open or leaky junctions to a normal state. The company is partnering with O. Colin Stine, PhD, a professor of epidemiology and public health at the University of Maryland, who has focused extensively on studying the molecular mechanisms that lead to bacterial invasion of the intestinal barrier as a result of increased intestinal permeability. “Larazotide is the only known molecule in late stage clinical trials that decreases intestinal permeability,” Stine said in a
Subscribe or to access all post and page content.